The content on this site is intended for healthcare professionals only
Dr Delia Guaqueta speaks to ecancer at the ASCO Direct Highlights 2022 Miami Symposium about some of the latest updates in treatment for the field of HER2-positive breast cancer.
Firstly, she discusses the promising results of the HER2CLIMB study with the use of tucatinib benefiting patients - even showing activity in those with brain metastases.
Dr Guaqueta then details the DESTINY-Breast03 study, which evaluates the use of trastuzumab deruxtecan for metastatic HER2-positive breast cancer, with the treatment improving progression-free survival in patients.
ASCO 2026: Breast cancer overview
Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Use of bispecifics and CAR T cells in South America
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Neo-adjuvant therapy for different cancers in the Philippines
